Detalhe da pesquisa
1.
TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer.
Breast Cancer Res Treat
; 164(3): 649-658, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28508185
2.
Use of a multiplexed immunoassay (PRO Onc assay) to detect HER2 abnormalities in circulating tumor cells of women with HER2-negative metastatic breast cancer: lack of response to HER2-targeted therapy.
Breast Cancer Res Treat
; 160(1): 41-49, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27632289
3.
A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC).
Clin Breast Cancer
; 22(3): 269-278, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34824002
4.
A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer.
Clin Breast Cancer
; 20(2): 89-97, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31932237
5.
IL1 Receptor Antagonist Controls Transcriptional Signature of Inflammation in Patients with Metastatic Breast Cancer.
Cancer Res
; 78(18): 5243-5258, 2018 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30012670
6.
A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice-daily regimen to treat patients with recurrent metastatic breast cancer.
Cancer
; 116(10): 2301-6, 2010 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20225231